Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-24-117493
Filing Date
2024-10-25
Accepted
2024-10-25 17:52:18
Documents
1
Period of Report
2024-10-21

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 8196
  Complete submission text file 0000950170-24-117493.txt   10875
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Issuer) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 1000 WILSON BOULEVARD, SUITE 3000 ARLINGTON VA 22209
Business Address 1000 WILSON BOULEVARD, SUITE 3000 ARLINGTON VA 22209 703-562-4000
Sands Capital Ventures, LLC (Reporting) CIK: 0001846444 (see all company filings)

State of Incorp.: DE
Type: 3 | Act: 34 | File No.: 001-39676 | Film No.: 241398015

Mailing Address 100 WILSON BLVD SUITE 3000 ARLINGTON VA 22209
Business Address
SANDS FRANK M. (Reporting) CIK: 0001870494 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39676 | Film No.: 241398014

Mailing Address C/O SANDS CAPITAL VENTURES, LLC 1000 WILSON BOULEVARD, SUITE 3000 ARLINGTON VA 22209
Business Address C/O SANDS CAPITAL VENTURES, LLC 1000 WILSON BOULEVARD, SUITE 3000 ARLINGTON VA 22209 703-562-4000
Sands Capital Life Sciences Pulse Fund II, L.P. (Reporting) CIK: 0001875620 (see all company filings)

State of Incorp.: E9
Type: 3 | Act: 34 | File No.: 001-39676 | Film No.: 241398016